Last reviewed · How we verify
IFN beta(24 weeks)
IFN beta(24 weeks) is a Interferon Small molecule drug developed by Tanabe Pharma Corporation. It is currently in Phase 3 development for Multiple sclerosis (relapsing-remitting or secondary progressive forms).
Interferon beta activates innate immune responses by binding to interferon-beta receptors on immune cells, enhancing antiviral and immunomodulatory activity.
IFN beta is used to treat conditions such as Relapsing Multiple Sclerosis, Multiple Sclerosis, and Relapsing Remitting Multiple Sclerosis. The mechanism of IFN beta is not specified in the provided facts, but it is listed as an intervention in various studies on ClinicalTrials.gov.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | IFN beta(24 weeks) |
|---|---|
| Sponsor | Tanabe Pharma Corporation |
| Drug class | Interferon |
| Target | Interferon-alpha/beta receptor (IFNAR) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
IFN beta is a type I interferon that binds to the interferon-alpha/beta receptor (IFNAR) on the cell surface, triggering JAK-STAT signaling pathways. This leads to upregulation of interferon-stimulated genes, enhanced natural killer cell activity, increased antigen presentation, and modulation of pro-inflammatory cytokine production. The net effect is enhanced innate immunity and potential anti-inflammatory effects depending on the disease context.
Approved indications
- Multiple sclerosis (relapsing-remitting or secondary progressive forms)
Common side effects
- Flu-like symptoms (fever, chills, myalgia)
- Injection site reactions
- Headache
- Fatigue
- Depression/mood changes
- Elevated liver enzymes
- Leukopenia
Key clinical trials
- Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC) (PHASE3)
- A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis (PHASE3)
- A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis (PHASE3)
- A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS) (PHASE2)
- Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a (PHASE2)
- Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial (PHASE4)
- BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis (PHASE2)
- Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IFN beta(24 weeks) CI brief — competitive landscape report
- IFN beta(24 weeks) updates RSS · CI watch RSS
- Tanabe Pharma Corporation portfolio CI
Frequently asked questions about IFN beta(24 weeks)
What is IFN beta(24 weeks)?
How does IFN beta(24 weeks) work?
What is IFN beta(24 weeks) used for?
Who makes IFN beta(24 weeks)?
What drug class is IFN beta(24 weeks) in?
What development phase is IFN beta(24 weeks) in?
What are the side effects of IFN beta(24 weeks)?
What does IFN beta(24 weeks) target?
Related
- Drug class: All Interferon drugs
- Target: All drugs targeting Interferon-alpha/beta receptor (IFNAR)
- Manufacturer: Tanabe Pharma Corporation — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Multiple sclerosis (relapsing-remitting or secondary progressive forms)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing